Your browser doesn't support javascript.
loading
Computational and Experimental Druggability Assessment of Human DNA Glycosylases.
Michel, Maurice; Visnes, Torkild; Homan, Evert J; Seashore-Ludlow, Brinton; Hedenström, Mattias; Wiita, Elisée; Vallin, Karl; Paulin, Cynthia B J; Zhang, Jiaxi; Wallner, Olov; Scobie, Martin; Schmidt, Andreas; Jenmalm-Jensen, Annika; Warpman Berglund, Ulrika; Helleday, Thomas.
Affiliation
  • Michel M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Visnes T; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Homan EJ; Department of Biotechnology and Nanomedicine, SINTEF Industry, N-7465 Trondheim, Norway.
  • Seashore-Ludlow B; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Hedenström M; Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 21 Stockholm, Sweden.
  • Wiita E; Department of Chemistry, Umeå University, S-901 87 Umeå, Sweden.
  • Vallin K; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Paulin CBJ; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Zhang J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Wallner O; Institute of Organic Chemistry, Clausthal University of Technology, Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany.
  • Scobie M; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Schmidt A; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
  • Jenmalm-Jensen A; Institute of Organic Chemistry, Clausthal University of Technology, Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany.
  • Warpman Berglund U; Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 21 Stockholm, Sweden.
  • Helleday T; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, S-171 76 Stockholm, Sweden.
ACS Omega ; 4(7): 11642-11656, 2019 Jul 31.
Article in En | MEDLINE | ID: mdl-31460271
ABSTRACT
Due to a polar or even charged binding interface, DNA-binding proteins are considered extraordinarily difficult targets for development of small-molecule ligands and only a handful of proteins have been targeted successfully to date. Recently, however, it has been shown that development of selective and efficient inhibitors of 8-oxoguanine DNA glycosylase is possible. Here, we describe the initial druggability assessment of DNA glycosylases in a computational setting and experimentally investigate several methods to target endonuclease VIII-like 1 (NEIL1) with small-molecule inhibitors. We find that DNA glycosylases exhibit good predicted druggability in both DNA-bound and -unbound states. Furthermore, we find catalytic sites to be highly flexible, allowing for a range of interactions and binding partners. One flexible catalytic site was rationalized for NEIL1 and further investigated experimentally using both a biochemical assay in the presence of DNA and a thermal shift assay in the absence of DNA.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Omega Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Omega Year: 2019 Document type: Article Affiliation country: